ArticleScientific reports2026
A novel spray-dried milk extracellular vesicles formulation with long-term immunomodulatory activity and functional stability.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Milk is a rich source of bioactive extracellular vesicles (EVs), with potential therapeutic functions for intestinal inflammation. A major limitation for the clinical use is their preservation, as they typically require storage at − 80 °C. To address this, our study aimed to develop a stable, room-temperature dry powder formulation of milk EVs (mEVs) that preserves their bioactivity. The mEVs were isolated via differential centrifugation with an EDTA cleaning step and subsequently spray-dried into microparticles using mannitol and leucine as excipients. The resulting microparticles were morphologically characterized as collapsed structures with a volume-weighted mean diameter of 11–20 µm and low aggregation. We found that the drying process did not cause molecular alterations, as the dried mEVs preserved protein and nucleic acid content comparable to that of unprocessed mEVs. Furthermore, the formulation showed minimal cytotoxicity on THP-1 cells (up to 1011 particles/mL), as measured by MTT assay. In a cellular inflammatory model, spray-dried mEVs stored for up to 18 months significantly reduced the gene expression of key pro-inflammatory cytokines (IL1B, IL6, CXCL8, and TNFA) to a degree comparable to unprocessed mEVs. This confirms the long-term functional stability of the dry mEV formulation. Our findings demonstrate that proper spray-drying approaches are a flexible and effective strategies for preserving mEVs, paving the way to the development of EVs loaded microparticles for a broad range of functional and therapeutic applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.